4564
OncoTherapy Science,Inc.
オンコセラピー・サイエンス
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(thousand JPY)
Mar 2021
332,477
Mar 2022
1,153,663
Mar 2023
1,134,903
Mar 2024
610,118
Mar 2025
750,048
Operating profit(thousand JPY)
Mar 2021
-1,637,936
Mar 2022
-2,052,637
Mar 2023
-1,106,415
Mar 2024
-1,120,800
Mar 2025
-797,936
Operating profit margin(%)
Mar 2021
-492.65
Mar 2022
-177.92
Mar 2023
-97.49
Mar 2024
-183.7
Mar 2025
-106.38
Profit before tax(thousand JPY)
Mar 2021
-1,560,012
Mar 2022
-2,570,306
Mar 2023
-1,116,420
Mar 2024
-1,285,713
Mar 2025
-813,125
Profit(thousand JPY)
Mar 2021
-1,561,636
Mar 2022
-2,571,541
Mar 2023
-1,118,644
Mar 2024
-1,288,138
Mar 2025
-815,285
Total assets(thousand JPY)
Mar 2021
3,368,102
Mar 2022
2,685,199
Mar 2023
1,511,438
Mar 2024
867,275
Mar 2025
1,155,203
Cash and cash equivalents(thousand JPY)
Mar 2021
2,899,092
Mar 2022
1,836,906
Mar 2023
1,117,635
Mar 2024
527,656
Mar 2025
833,883
Cash flows from operating activities(thousand JPY)
Mar 2021
-1,762,629
Mar 2022
-2,073,224
Mar 2023
-794,901
Mar 2024
-1,227,990
Mar 2025
-815,021
Cash flows from investing activities(thousand JPY)
Mar 2021
-52,225
Mar 2022
-467,928
Mar 2023
-20,319
Mar 2024
-33,354
Mar 2025
-279
Cash flows from financing activities(thousand JPY)
Mar 2021
-
Mar 2022
1,478,967
Mar 2023
95,950
Mar 2024
671,365
Mar 2025
1,121,527
Return on equity(-)
Mar 2021
-
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Equity ratio(%)
Mar 2021
88.8
Mar 2022
70.6
Mar 2023
51.5
Mar 2024
32.2
Mar 2025
57
Earnings per share(JPY per share)
Mar 2021
-8.86
Mar 2022
-13.72
Mar 2023
-5.81
Mar 2024
-6.05
Mar 2025
-3.12
Net assets per share(JPY per share)
Mar 2021
16.96
Mar 2022
9.84
Mar 2023
4.04
Mar 2024
1.28
Mar 2025
2.42
Dividend per share(-)
Mar 2021
-
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Payout ratio(-)
Mar 2021
-
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.